Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy

被引：2

作者：

Perez, Jorge M. Ramos ^{[1
]}

Tinajero, Jose ^{[2
]}

Ngo, Dat ^{[2
]}

Zhang, Jianying ^{[3
,4
]}

Koller, Paul B. ^{[1
]}

Agrawal, Vaibhav ^{[1
]}

Pourhassan, Hoda ^{[1
]}

Al Malki, Monzr M. ^{[5
]}

Salhotra, Amandeep ^{[1
]}

Ali, Haris ^{[1
]}

Aribi, Ahmed ^{[1
]}

Sandhu, Karamjeet S. ^{[1
]}

Arslan, Shukaib ^{[1
]}

Otoukesh, Salman ^{[1
]}

Amanam, Idoroenyi ^{[1
]}

Artz, Andrew S. ^{[1
]}

Becker, Pamela S. ^{[1
]}

Stewart, Forrest M. ^{[1
]}

Smith, Eileen P. ^{[1
]}

Curtin, Peter ^{[1
]}

Forman, Stephen J. ^{[1
]}

Nakamura, Ryotaro ^{[1
]}

Pullarkat, Vinod A. ^{[1
]}

Marcucci, Guido ^{[1
]}

Stein, Anthony S. ^{[1
]}

Aldoss, Ibrahim ^{[1
]}

Ball, Brian J. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Pharm, Duarte, CA USA

[3] City Hope Natl Med Ctr, Dept Computat & Quantitat Med BRI, Duarte, CA 91010 USA

[4] City Hope Natl Med Ctr, Dept Computat & Quantitat Med, Beckman Res Inst, Duarte, CA USA

[5] City Hope Med Ctr, Duarte, CA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-170867

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

615

引用

页码：9039 / 9040

页数：2

共 50 条

[1] 10-day vs 5-day decitabine: equivalence cannot be concluded
Huls, Gerwin
Suciu, Stefan
Wijermans, Pierre
Kicinski, Michal
Luebbert, Michael
[J]. LANCET HAEMATOLOGY, 2019, 6 (04): : E177 - E177
[2] Outcomes of 10-day decitabine with venetoclax for AML.
Coltoff, Alexander
Baratam, Praneeth
Green, Kimberly Michelle
Davis, James A.
Smith, Deidra
Gaffney, Kelly
Dougherty, Elizabeth
Milligan, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
DiNardo, Courtney D.
Maiti, Abhishek
Rausch, Caitlin R.
Pemmaraju, Naveen
Naqvi, Kiran
Daver, Naval G.
Kadia, Tapan M.
Borthakur, Gautam
Ohanian, Maro
Alvarado, Yesid
Issa, Ghayas C.
Montalban-Bravo, Guillermo
Short, Nicholas J.
Yilmaz, Musa
Bose, Prithviraj
Jabbour, Elias J.
Takahashi, Koichi
Burger, Jan A.
Garcia-Manero, Guillermo
Jain, Nitin
Kornblau, Steven M.
Thompson, Philip A.
Estrov, Zeev
Masarova, Lucia
Sasaki, Koji
Verstovsek, Srdan
Ferrajoli, Alessandra
Weirda, William G.
Wang, Sa A.
Konoplev, Sergej
Chen, Zhining
Pierce, Sherry A.
Ning, Jing
Qiao, Wei
Ravandi, Farhad
Andreeff, Michael
Welch, John S.
Kantarjian, Hagop M.
Konopleva, Marina Y.
[J]. LANCET HAEMATOLOGY, 2020, 7 (10): : E724 - E736
[4] Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Short, Nicholas J.
Kantarjian, Hagop M.
Loghavi, Sanam
Huang, Xuelin
Qiao, Wei
Borthakur, Gautam
Kadia, Tapan M.
Daver, Naval
Ohanian, Maro
Dinardo, Courtney D.
Estrov, Zeev
Kanagal-Shamanna, Rashmi
Maiti, Abhishek
Benton, Christopher B.
Bose, Prithviraj
Alvarado, Yesid
Jabbour, Elias
Kornblau, Steven M.
Pemmaraju, Naveen
Jain, Nitin
Gasior, Yvonne
Richie, Mary Ann
Pierce, Sherry
Cortes, Jorge
Konopleva, Marina
Garcia-Manero, Guillermo
Ravandi, Farhad
[J]. LANCET HAEMATOLOGY, 2019, 6 (01): : E29 - E37
[5] Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML
Suo, Xiaohui
Bai, Guanchen
Zhao, Xingli
Zhang, Congcong
Li, Yinling
Gao, Sifeng
Zhang, Jilei
Lu, Xinxiao
Yuan, Linyu
Mi, Yingchang
Liu, Kaiqi
[J]. BLOOD, 2023, 142
[6] EFFICACY OF DECITABINE IN 10-DAY REGIMEN IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Moreno de Gusmao, B.
Esteves, I.
Santos, F. P. S.
Petrolli, M.
Ferreira, F.
Galvao, C., Jr.
Perini, G.
Hyppolito, J.
Helman, R.
Hamersclak, N.
[J]. LEUKEMIA RESEARCH, 2015, 39 : S113 - S113
[7] EFFICACY OF DECITABINE IN 10-DAY REGIMEN IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
Moreno De Gusmao, B.
Esteves, I.
Petrolli, M.
Hyppolito, J.
Santos, F.
Ferreira, F.
Perini, G.
Helman, R.
Hamerschlak, N.
[J]. HAEMATOLOGICA, 2015, 100 : 653 - 653
[8] Efficacy and tolerability of 5-day vs. 10-day treatment with cefixime suspension in children with acute otitis media
Adam, D
[J]. DRUGS OF TODAY, 2000, 36 : 29 - 33
[9] Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
Huls, Gerwin
Chitu, Dana A.
Pabst, Thomas
Klein, Saskia K.
Stussi, Georg
Griskevicius, Laimonas
Valk, Peter J. M.
Cloos, Jacqueline
van de Loosdrecht, Arjan A.
Breems, Dimitri
van Lammeren-Venema, Danielle
van Zeventer, Isabelle
Boersma, Rinske
Jongen-Lavrencic, Mojca
Fehr, Martin
Hoogendoorn, Mels
Manz, Markus G.
Sohne, Maaike
Kooy, Rien van Marwijk
Deeren, Dries
van der Poel, Marjolein W. M.
Legdeur, Marie Cecile
Tick, Lidwine
Chalandon, Yves
Ammatuna, Emanuele
Blum, Sabine
Lowenberg, Bob
Ossenkoppele, Gert J.
[J]. BLOOD ADVANCES, 2020, 4 (18) : 4267 - 4277
[10] A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia
Short, Nicholas J.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Borthakur, Gautam
Kadia, Tapan
Huang, Xuelin
Daver, Naval
DiNardo, Courtney D.
Ferrajoli, Alessandra
Wierda, William G.
Estrov, Zeev
Benton, Christopher B.
Bose, Prithviraj
Alvarado, Yesid
Kornblau, Steven
Ohanian, Maro
Gaisor, Yvonne
Richie, Mary Ann
Pierce, Sherry
Jabbour, Elias J.
Cortes, Jorge E.
Ravandi, Farhad
[J]. BLOOD, 2017, 130

← 1 2 3 4 5 →